Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central nervous process, conolidine modulates alternate molecular targets. A Science Innovations study found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://zionhbill.answerblogs.com/38161067/not-known-factual-statements-about-conolidin-to-replace-traditional-painkillers